Olaparib Tablets Exporter India | PARP Inhibitor Precision Oncology Supplier

Product Overview
Key Features
Therapeutic Uses
Dosage Form Advantages

Olaparib tablets are advanced targeted oncology medicines classified as PARP inhibitors, primarily used in the treatment of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations. The formulation works by blocking the PARP enzyme, preventing DNA repair in cancer cells and leading to their destruction, making it a key option in precision oncology.

In international pharmaceutical trade, Olaparib tablets exporter India and PARP inhibitor supplier India are highly searched by oncology distributors and specialty drug importers. Genliva Wellness LLP, Himatnagar, operates as a pharma exporter India precision oncology medicines partner, supplying innovative targeted therapies to global healthcare markets with consistent quality and regulatory compliance.

Olaparib tablets are a targeted anticancer therapy formulated as a PARP inhibitor that interferes with DNA repair in cancer cells. The formulation is designed for precision oncology, particularly in cancers with specific genetic mutations.

PARP inhibitor targeting DNA repair mechanisms in tumor cells
Selectively acts on cancer cells with BRCA or related mutations
Helps induce cancer cell death by blocking repair pathways
Oral formulation for convenient and continuous therapy
Provides controlled and consistent therapeutic action
Manufactured under stringent cGMP and quality standards

This medication is used in the treatment of certain genetically defined cancers, especially where DNA repair pathways are impaired. It is prescribed as part of advanced oncology treatment protocols.

BRCA-mutated ovarian cancer (maintenance and advanced therapy)
HER2-negative metastatic breast cancer with BRCA mutation
Prostate cancer with homologous recombination repair mutations
Pancreatic cancer (selected cases)
Helps delay disease progression and recurrence

The formulation offers precision-targeted therapy with improved outcomes in selected patient populations. It supports personalized cancer treatment approaches.

Targets cancer cells with specific genetic mutations
Helps extend progression-free survival
Oral therapy improves patient convenience and adherence
Suitable for long-term maintenance therapy
Predictable and consistent therapeutic performance
Stable formulation suitable for global oncology supply